ATOX1 and breast carcinoma: Taken together, cytoplasmatic ATOX1 has the potential to be a predictive biomarker for TM treatment of breast cancer patients at high risk of recurrence, such that patients with high cytoplasmatic ATOX1 levels in the cancer tissue might benefit from TM treatment.